HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.
- The Company anticipates the first patient will be enrolled in the fourth quarter of 2024.
- Effective April 25, 2024, HOOKIPA regained full control of the associated intellectual property portfolio and has full collaboration and licensing rights for this program.
- HOOKIPA received FDA clearance of its IND application in the fourth quarter of 2023 and expects to initiate a Phase 1 clinical trial of HB-500 in people with HIV in the second quarter of 2024.
- On January 29, 2024, HOOKIPA provided an update on its business priorities and oncology partnership programs.